Arbutus Biopharma Corp Depreciation and Amortization
Arbutus Biopharma Corp (ABUS) reported Depreciation and Amortization of $22.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:DepreciationDepletionAndAmortization · last filed 2026-08-12
- Arbutus Biopharma Corp depreciation, depletion and amortization for the quarter ending 2026-06-30 was $11.00K, a 0.00% change year-over-year.
- Arbutus Biopharma Corp depreciation, depletion and amortization for the quarter ending 2026-03-31 was $11.00K, a 96.67% decline year-over-year.
- Arbutus Biopharma Corp depreciation, depletion and amortization for the quarter ending 2025-09-30 was $11.00K, a 96.73% decline year-over-year.
- Arbutus Biopharma Corp depreciation, depletion and amortization for the quarter ending 2025-06-30 was $11.00K, a 96.91% decline year-over-year.
| Period end | Depreciation, Depletion and Amortization 3 month | Depreciation, Depletion and Amortization 6 month | Depreciation, Depletion and Amortization 9 month |
|---|---|---|---|
| 2026-06-30 | $11.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $22.00K 10-Q · filed 2026-08-12 | |
| 2026-03-31 | $11.00K 10-Q · filed 2026-05-13 | ||
| 2025-09-30 | $11.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $22.00K derived: sum of 2 quarters · filed 2026-08-12 | $352.00K 10-Q · filed 2025-11-13 |
| 2025-06-30 | $11.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $341.00K 10-Q · filed 2026-08-12 | |
| 2025-03-31 | $330.00K 10-Q · filed 2026-05-13 | ||
| 2024-09-30 | $336.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $692.00K derived: sum of 2 quarters · filed 2025-11-13 | $1.05M 10-Q · filed 2025-11-13 |
| 2024-06-30 | $356.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $711.00K 10-Q · filed 2025-08-06 | |
| 2024-03-31 | $355.00K 10-Q · filed 2025-05-14 | ||
| 2023-09-30 | $369.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $711.00K derived: sum of 2 quarters · filed 2024-11-06 | $1.04M 10-Q · filed 2024-11-06 |
| 2023-06-30 | $342.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $676.00K 10-Q · filed 2024-08-08 | |
| 2023-03-31 | $334.00K 10-Q · filed 2024-05-02 | ||
| 2022-09-30 | $343.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $726.00K derived: sum of 2 quarters · filed 2023-11-07 | $1.12M 10-Q · filed 2023-11-07 |
| 2022-06-30 | $383.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $777.00K 10-Q · filed 2023-08-03 | |
| 2022-03-31 | $394.00K 10-Q · filed 2023-05-04 | ||
| 2021-09-30 | $447.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $883.00K derived: sum of 2 quarters · filed 2022-11-09 | $1.33M 10-Q · filed 2022-11-09 |
| 2021-06-30 | $436.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $879.00K 10-Q · filed 2022-08-04 | |
| 2021-03-31 | $443.00K 10-Q · filed 2022-05-05 | ||
| 2020-09-30 | $490.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $991.00K derived: sum of 2 quarters · filed 2021-11-04 | $1.49M 10-Q · filed 2021-11-04 |
| 2020-06-30 | $501.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $1.00M 10-Q · filed 2021-08-05 | |
| 2020-03-31 | $500.00K 10-Q · filed 2021-05-05 | ||
| 2019-09-30 | $507.00K 10-Q · filed 2019-11-06 | $1.01M derived: sum of 2 quarters · filed 2019-11-06 | $1.52M 10-Q · filed 2020-11-05 |
| 2019-06-30 | $505.00K 10-Q · filed 2019-08-05 | $1.01M 10-Q · filed 2020-08-07 | |
| 2019-03-31 | $509.00K 10-Q · filed 2020-05-11 | ||
| 2018-09-30 | $497.00K 10-Q · filed 2019-11-06 | $1.07M derived: sum of 2 quarters · filed 2019-11-06 | $1.68M 10-Q · filed 2019-11-06 |
| 2018-06-30 | $578.00K 10-Q · filed 2019-08-05 | $1.18M 10-Q · filed 2019-08-05 | |
| 2018-03-31 | $602.00K 10-Q · filed 2019-05-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |